A Multicenter Real-Life Evaluation of Safety and Effectiveness of the Antibody-Drug Conjugate Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
The real-life data reported in this paper confirm the randomized trial results regarding efficacy and tolerability. The authors stressed the importance of the early identification of severe side effects in managing these patients.
Authors
- Maria Rosaria Valerio (ORCID: https://orcid.org/0000-0003-3589-4684)
- Federica Martorana (ORCID: https://orcid.org/0000-0001-5062-2914)
- Paolo Vigneri (ORCID: https://orcid.org/0000-0002-5943-6066)
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-0758-8033)
- Giuseppina Scandurra
- Ida Paris
- G Bini (ORCID: https://orcid.org/0000-0003-2641-0123)
- Oriana Maiorana
- Francesco Giotta (ORCID: https://orcid.org/0000-0001-5284-5281)
- Maria V. Sanò
- V. Leonardi
- Annabella Curaba
- Vittorio Gebbia (ORCID: https://orcid.org/0000-0001-8406-9416)
Institutions
- Università degli Studi di Enna Kore (IT)
- Agostino Gemelli University Polyclinic (IT)
- University of Catania (IT)
- Ospedale Vincenzo Cervello (IT)
- Nuovo Ospedale San Giovanni di Dio (IT)
- Ospedale Cannizzaro (IT)
- Azienda di Rilievo Nazionale ed Alta Specializzazione (IT)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Fondazione Humanitas per la Ricerca (IT)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1097/coc.0000000000001201
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00